Global Antibody Discovery Market to Soar from USD 1.9B in 2024 to USD 3.3B by 2030

Release time: 2025-09-02 View volume: 371

Recent market analyses estimate the antibody discovery market at USD 1.9 billion (2024) with growth to USD 3.3 billion by 2030—a compound annual growth rate (CAGR) of about 9.8%. Momentum is driven by strong pipelines in monoclonal antibodies, rapid uptake of bispecifics, and accelerated investment in antibody–drug conjugates (ADCs).

Market Size (2024)

$1.9B

Forecast (2030)

$3.3B

CAGR (2024–2030)

~9.8%

Growth

What’s Driving the Growth?

1) Diversified Modalities

mAbs: Continued clinical success and lifecycle management for established targets.
Bispecifics: Expanding into oncology and autoimmune indications with novel pairings (e.g., CD3 x tumor antigens).
ADCs: Better linkers/payloads and target validation reduce attrition; more programs move to pivotal stages.

2) Faster, Smarter Discovery

Single B-cell platforms and naïve/immune libraries shorten timelines and improve epitope coverage.
AI/ML-assisted design speeds affinity maturation, developability screening, and liability prediction.
Stable cell line and process intensification de-risk scale-up into preclinical/clinical supply.

Market Snapshots

By Modality

Segment	Trend
Monoclonal Antibodies (mAbs)	Stable growth; new targets & next-gen formats sustain demand
Bispecific Antibodies	Fastest growth; oncology & immunology pipelines expanding
ADCs	Strong momentum; improved linkers/payloads & targeted indications

By Discovery Method

Approach	Notes
Single B-cell	Rapid hit-to-lead; native pairing preserves function
Phage/Yeast Display	Large library diversity; efficient panning & optimization
Hybridoma	Reliable for animal immunization routes & reagent antibodies
In-silico/AI	Design/triage for affinity, specificity, and developability

By Region

Region	Outlook
North America	Largest share; robust venture & clinical activity
Europe	Strong academia–industry networks; CDMO capacity expanding
Asia-Pacific	Fastest growth; investment in discovery platforms and ADC pipelines

AtaGenix Insight

As the antibody discovery market expands, AtaGenix stands ready to accelerate customer programs across discovery, screening, and engineering—offering efficient, cost-effective platforms tailored to next-generation biologics. Our integrated capabilities include:

Single B-cell discovery (mouse, rabbit, human samples) and high-throughput sequencing
Naïve/immune library construction, phage display panning, and epitope binning
Humanization, affinity maturation, developability assessment, and stability engineering
Recombinant protein expression (E. coli / Yeast / Mammalian / Insect) and purification
Stable cell line development and upstream process optimization

Explore Antibody Discovery

Talk to our scientists to map an accelerated path from hit to IND-enabling studies.

Sources

Clinical Trial Vanguard – Market/Clinical pipeline roundup

Note: Figures (USD 1.9B in 2024; USD 3.3B in 2030; ~9.8% CAGR) reflect aggregated estimates from the sources above; methodologies may differ among publishers.

About Us

Messages

By Method

By Application